Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma

Molecular Cancer Therapeutics

Volumn 2, Issue 4, 2003, Pages 401-408

  Kraker, Alan J ^a   Mizzen, Craig A ^b,c   Hartl, Brian G ^a   Miin, Johnson ^a   Allis, C David ^b   Merriman, Ronald L ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDINALINE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE; PHENYLENEDIAMINE DERIVATIVE;

ACETYLATION; ARTICLE; CELL NUCLEUS; CHEMICAL MODEL; CHEMISTRY; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; HUMAN; IC 50; METABOLISM; SERODIAGNOSIS; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PHENYLENEDIAMINES; PRECIPITIN TESTS; TIME FACTORS;

EID: 0141996376     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Wolffe, A. P. Chromatin (Ed. 3). Academic Press, Inc.: San Diego, 1998.
2. Cheung, P., Allis, C. D., and Sassone-Corsi, P. Signaling to chromatin through histone modifications. Cell, 103: 263-271, 2000.
3. Wolffe, A. P., and Hayes, J. J. Chromatin disruption and modification. Nucleic Acids Res., 27: 711-720, 1999. (Pubitemid 29209356)
4. Davie, J. R, and Spencer, V. A. Control of histone modifications. J. Cell. Biochem. Supp., 32/33: 141-148, 1999. (Pubitemid 30041820)
5. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (Lond.), 391: 811-814, 1998. (Pubitemid 28099682)
6. Borrow, J., Stanton, V. P., Jr., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S., Civin, C. I., Disteche, C., Dube, I., Frischauf, A. M., Horsman, D., Mitelman, F., Volinia, S., Watmore, A. E., and Housman, D. E. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet., 14: 33-41, 1996.
7. Roth, S. Y., Denu, J. M., and Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem., 70: 81-120, 2001. (Pubitemid 32662206)
8. Grant, P. A., and Berger, S. L. Histone acetyltransferase complexes. Semin. Cell Dev. Biol., 10: 169-177, 1999. (Pubitemid 129502408)
9. Mizzen, C. A., and Allis, C. D. Linking histone acetylation to transcriptional regulation. Cell. Mol. Life Sci., 54: 6-20, 1996.
10. Jacobson, R. H., Ladurner, A. G., King, D. S., and Tjian, R. Structure and function of a human TAFII250 double bromodomain module. Science (Wash. DC), 288: 1422-1425, 2000. (Pubitemid 30366328)
11. Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., and Zhou, M. M. Structure and ligand of a histone acetyltransferase bromodomain. Nature (Lond.), 399: 491-496, 1999. (Pubitemid 29258857)
12. Clarke, A. S., Lowell, J. E., Jacobson, S. J., and Pillus, L. Esa1p is an essential histone acetyltransferase required for cell cycle progression. Mol. Cell. Biol., 19: 2515-2526, 1999. (Pubitemid 29144495)
13. Smith, E. R., Eisen, A., Gu, W., Sattah, M., Pannuti, A., Zhou, J., Cook, R. G., Lucchesi, J. C., and Allis, C. D. ESA1 is a histone acetyltransferase that is essential for growth in yeast. Proc. Natl. Acad. Sci. USA, 95: 3561-3565, 1998. (Pubitemid 28173167)
14. Cress, W. D., and Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol., 184: 1-16, 2000. (Pubitemid 30349623)
15. Taunton, J., Hassig, C. A., and Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science (Wash. DC), 272: 408-411, 1996. (Pubitemid 26138177)
16. Li, X., Yoshida, M., Beppu, T., and Lotan, R. Modulation of growth and differentiation of human colon carcinoma cell by histone deacetylase inhibitory trichostatins. Int. J. Oncol., 8: 431-437, 1996. (Pubitemid 26083101)
17. Yoshida, M., Horinouchi, S., and Beppu, T. TSA and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structures and function. Bioessays, 17: 423-430, 1995.
18. Taunton, J., Collins, J. L., and Schreiber, S. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J. Am. Chem. Soc., 118: 10412-10422, 1996. (Pubitemid 26381223)
19. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998. (Pubitemid 28135844)
20. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic. C. R. Acad. Sci. (Paris), 322: 161-165, 1999.
21. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., and Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem., 42: 3001-3003, 1999. (Pubitemid 29370445)
22. Saito, A., Yamashita, T., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O., A synthetic inhibitor of histone deacetylase. MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999. (Pubitemid 29190381)
23. Jung, M., Brosch, G., Kölle, D., Scherf, H., Gerhäuser, C., and Loidl, P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem., 42: 4669-4679, 1999. (Pubitemid 29530020)
24. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (Bethesda), 92: 1210-1216, 2000. (Pubitemid 30627729)
25. Wozniak, A., O'Shaughnessy, J., Fiorica, J., and Grove, W. Phase II trial of CI-994 in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 18: 487a, 1999.
26. O'Shaughnessy, J., Flaherty, L., Fiorica, J., and Grove, W. Phase II trial of CI-994 in patients (pts) with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 18: 349a, 1999.
27. Zalpuski, M., O'Shaughnessy, J., Vulkeja, A., Shields, A., Diener, K., and Grove, W. Phase II trial of CI-994 in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 19: 285a, 2000.
28. Prakash, S., Forster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L., Zalupski, M., Radulovic, L., Valdivieso, M., and LoRusso, P. M. Chronic oral administration of CI-994: a Phase 1 study. Investig. New Drugs, 19: 1-11, 2001. (Pubitemid 32209780)
29. Rummel, S. A., Kraker, A. J., Steinkampf, R. W., Hook, K. E., and Klohs, W. D., Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int. J. Cancer, 62: 636-642, 1995.
30. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesh, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990. (Pubitemid 20213250)
31. Hay, C. W., and Candido, E. P. M. Histone deacetylase. J. Biol. Chem., 256: 3726-3734, 1983.
32. Sassone-Corsi, P., Mizzen, C. A., Cheung, P., Crosio, C., Monaco, L., Jacquot, S., Hanauer, A., and Allis, C. D. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science (Wash. DC), 285: 886-891, 1999. (Pubitemid 29381988)
33. Wang, L., Mizzen, C., Ying, C., Candau, R., Barlev, N., Brownell, J., Allis, C. D., and Berger, S. L. Histone acetyltransferase activity is conserved between yeast and human GCN5 and is required for complementation of growth and transcriptional activation. Mol. Cell. Biol., 17: 519-527, 1997. (Pubitemid 26425641)
34. Mizzen, C. A., Brownell, J. E., and Allis, C. D. Histone acetyltransferases: preparation of substrates and assay procedures. Methods Enzymol., 304: 675-696, 1999. (Pubitemid 29268912)
35. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-17179, 1990.
36. Kim, Y. B., Lee, K-H., Sugita, K., Yoshida, M., and Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 18: 2461-2470, 1999. (Pubitemid 29206159)
37. Khochbin, S., Verdel, A., Lemercier, C., and Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev., 11: 162-166, 2001. (Pubitemid 32209200)
38. Barlow, A. L., van Drunen, C. M., Johnson, C. A., Tweedie, S., Bird, A., and Turner, B. M. dSIR2 and dHDAC6: two novel, inhibitor-resistant deacetylases in Drosophila melanogaster. Exp. Cell Res., 265: 90-103, 2001. (Pubitemid 32989067)
39. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., and Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA, 98: 87-92, 2001. (Pubitemid 32095868)
40. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., and Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res., 241: 126-133, 1998. (Pubitemid 28366586)
41. Foster, B. J., Jones, L., Wiegand, R., LoRusso, P. M., and Corbett, T. H. Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (N-acetyldinaline). Investig. New Drugs, 15: 187-194, 1997. (Pubitemid 27453873)
42. Seelig, M. H., and Berger, M. R. Efficacy of Dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur. J. Cancer, 32A: 1968-1976, 1996. (Pubitemid 26361693)
43. Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., and Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem., 274: 34940-34947, 1999. (Pubitemid 129509542)
44. Curtin, M. L., Current patent status of histone deacetylase inhibitors. Exp. Opin. Ther. Patents, 12: 1375-1383, 2002.
45. Remiszewski, S. W., Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Disc. Dev., 5: 487-499, 2002. (Pubitemid 36748979)
46. Laherty, C. D., Yang, W. M., Sun, J. M., Davie, J. R., Seto, E., and Eisenman, R. N. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell, 89: 349-356, 1997. (Pubitemid 27220879)
47. Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell, 89: 357-364, 1997. (Pubitemid 27220880)
48. Zhang, Y., LeRoy, G., Seelig, H. P., Lane, W. S., and Reinberg, D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell, 95: 279-289, 1998. (Pubitemid 28473788)
49. Galasinski, S. C., Resing, K. A., Goodrich, J. A., and Ahn, N. G. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J. Biol. Chem., 277: 19618-19626, 2002. (Pubitemid 34967475)
50. Humphrey, G. W., Wang, Y., Russanova, V. R., Hirai, T., Qin, J., Nakatani, Y., and Howard, B. H. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem., 276: 6817-6824, 2001.
51. th European workshop on drug metabolism. Basel, Switzerland, September 16-21, 1990.
52. Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., and La Quaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res., 59: 4392-4399, 1999. (Pubitemid 29418759)
53. Howard, C. T., Guisbert, E. A., Dykes, D. J., and Merriman, R. L. In vivo antitumor activity of CI-994 (N-acetyldinaline, GOE5549) alone and in combination with Adriamycin against mammary adenocarcinoma 16C. Proc. Am. Assoc. Cancer Res., 39: 311, 1998.
54. Howard, C. T., Guisbert, E. A., Schaefer, J. S., and Merriman, R. L. In vivo antitumor activity of CI-994 (N-acetyldinaline, GOE 5549) alone and in combination with gemcitabine against LC12 squamous cell lung carcinoma. Proc. Am. Assoc. Cancer Res., 40: 590, 1999.